Ethanercept: A review of its use in rheumatoid arthritis

Drugs

Volumn 57, Issue 6, 1999, Pages 945-966

  Jarvis, Blair ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; HYBRID PROTEIN; IMMUNOGLOBULIN G1; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; COUGHING; DISEASE ACTIVITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DYSPEPSIA; HEADACHE; HEALTH CARE COST; HUMAN; INFECTION; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; JUVENILE RHEUMATOID ARTHRITIS; LACTATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PREGNANCY; RASH; RHEUMATOID ARTHRITIS; RHINITIS; SINUSITIS; SUBCUTANEOUS DRUG ADMINISTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTIGO; ANIMAL; CHEMISTRY; DRUG EFFECT; FEMALE; INFORMATION PROCESSING; MILK; PHYSIOLOGY; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DATA COLLECTION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MILK; PREGNANCY; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033144422     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957060-00014     Document Type: Article

References (115)

1. 1. McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in curly rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998; 57: 350-6
2. 2. van der Heijde DMFM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl. 2: 74-8
3. 3. Kingsley G, Panayi GS. Joint destruction in rheumatoid arthritis: biological bases. Clin Exp Rheumatol 1997; 15 Suppl. 17: S3-14
4. 4. Buckley CD. Treatment of rheumatoid arthritis. BMJ 1997 Jul 26; 315: 236-8
5. 5. Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis. N Engl J Med 1997 Jul 17; 337: 195-7
6. 6. O'Dell JR. Anticytokine therapy a new era in the treatment of rheumatoid arthritis? N Engl J Med 1999 Jan 28; 340: 310-2
7. 7. Eigler A, Sinba B, Hartmann G, et al. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997; 18: 487-92
8. 8. Deleuran BW. Cytokines in rheumatoid arthritis: localization in arthritic joint tissue and regulation in vitro. Scand J Rheumatol 1996; 25 Suppl. 104: 1-38
9. 9. Firestein GS. Invasive fibrobast-like synoviocytes in rheumaloid arthritis: passive responders or transformed aggressors? Arthritis Rheum 1996; 39: 1781-90
10. 10. Feldmann M, Brennan FM, Williams RO, et al. Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNFα antibody therapy and its mechanism of action. J Inflammation 1996; 47: 90-6
11. 11. Palcolog E. Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNFα antibody in rheumatoid arthritis. J Clin Pathol Mol Pathol 1997; 50: 225-33
12. 12. Starkebaum G. Role of cytokines in rheumatoid arthritis. Sci Mod 1998 Mar-Apr; 5: 6-15
13. 13. McQueen FM. The use of biologies in the treatment of rheumatoid arthritis (RA) - the good news and the bad news. Aust N Z J Med 1997; 27: 175-84
14. 14. Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 1994; 6: 407-13
15. 15. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717-25
16. 16. Cope AP. Regulation of autoimmunity by proinflammatory cytokincs. Curr Opin Immunol 1998; 10:669-76
17. 17. Jones EY, Stuart DI, Walker NPC. Structure of tumour necrosis factor. Nature 1998 Mar 16; 338: 225-8
18. 18. Poltorak A, Peppel K, Beutler B. Receptor-mediated label-transfer assay (RELAY); a novel method for the detection of plasma tumor necrosis factor at attomolar concentrations. J Immunol Methods 1994; 169: 93-9
19. 19. Maury CPJ, Teppo A-M. Cachectin/tumour necrosis factor-α in the circulation of patients with rheumatic disease. Int J Tissue React 1989; XI (4): 189-93
20. 20. Saxne T, Palladino MAJ, Heinegard D, et al. Detection of tumor necrosis factor a but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 1041-5
21. 21. Barrera P, Boerbooms AMT, Janssen EM, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and inlerleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993; 36; 1070-9
22. 22. Beckham JC, Caldwell DS, Peterson BL, et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-α, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992; 12: 353-61
23. 23. Thornton SC, Por SB, Penny R, et al. Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumour necrosis factor-alpha. Clin Exp Immunol 1991; 86: 79-86
24. 24. Husby G, Williams Jr RC. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmunity 1988; 1: 363-71
25. 25. Chu CQ. Field M, Feldmann M, et al. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1125-32
26. 26. Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. J Clin Invest 1990; 86: 1790-8
27. 27. Shingu M, Nagai Y, Isayama T, et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells und endothelial cells. Clin Exp Immunol 1993; 94: 145-9
28. 28. Macnaul KL, Chartrain N, Lark M, et al. Differential effects of IL-1 and TNF alpha on the expression of stromelysin, collagenase and their inhibitor, TIMP, in rheumatoid human synovial fibroblasts. Matrix Suppl 1992; 1: 198-9
29. 29. Ahmadzadeh N, Shingu M, Nobunaga M. The effect of recombinant tumor necrosis factor-α on superoxide and metalloproteinase production by synovial cells and chondrocytes. Clin Exp Rheumatol 1990; 8: 387-91
30. 2 production by synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163-8
31. 31. Saklatvala J. Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1988; 322: 547-9
32. 32. Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of hone formation in vitro by human tumour necrosis factors. Nature 1986; 319; 516-8
33. 33. Brennan FMB, Chantry D, Jackson A, et al. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989 Jul 29; 11: 244-7
34. 34. van Lent PLEM, van de Loo FAJ, Holthuysen AEM, et al. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 1995; 22: 2250-8
35. 35. Keffer J, Probert L. Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10; 4025-31
36. 36. Piguel PF, Grau GE, Vesin C, et al. Evolution of collagen arthritis in mice is arrested hy treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992; 77: 510-4
37. 37. Williams RO, Mason LJ, Feldmann M, et al. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994; 91: 2762-6
38. 38. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992; 89: 9784-8
39. 39. Joosten LAB, Helsen MMA, van de Loo FAJ, et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. Arthritis Rheum 1996; 39: 797-809
40. 40. Ellion MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993; 36: 1681-90
41. 41. Deleuran BW, Chu C-Q. Field M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum 1992; 35: 1170-8
42. 42. Butler DM, Feldmann M, Di Padova F, et al. p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other Fihroblasts. Eur Cytokine Netw 1994; 5: 441-8
43. 43. Seckinger P, Isaaz S, Dayer JM. A human inhibitor of tumor necrosis factor alpha. J Exp Med 1988; 167: 1511-6
44. 44. Olsson I, Lantz M, Nilsson E, et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989; 42: 270-5
45. 45. Engelmann H, Aderka D, Rubinstein M, et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264; 11974-80
46. 46. Ferrante A, Hauptmann B, Seckinger P, et al. Inhibition of tumour necrosis factor alpha (TNF-α)-induced neutrophil respiratory burst by a TNF inhibior. Immunology 1991; 72: 440-2
47. 47. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160-9
48. 48. Heilig B, Wermann M, Gallati H, et al. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis Clin Invest 1992; 70: 22-7
49. 49. Roux-Lombard P, Punzi L, Hasler F, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485-9
50. 50. Taylor DJ. Cytokine combinations increase p75 tumor necrosis factor receptor binding and stimulate receptor shedding in rheumatoid synovial fibroblasts. Arthritis Rheum 1994; 37: 232-5
51. 51. Enbrel Prescribing Information. Immunex Corporation, Seattle, Washington, USA, NOv 1998
52. 52. Fisher Jr CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996 Jun 27; 334: 1697-702
53. 53. Eason JD, Pascual M, Wee S, et al. Evaluation of recombinant human soluble numeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation 1996; 61 (2): 224-8
54. 54. Novak EJ, Blosch CM, Perkins JD, et al. Recombinant human tumor necrosis factor receptor fc fusion protein therapy in kidney transplant recipients undergoing OKT3 induction therapy. Transplantation 1998 Dec 27; 66: 1732-5
55. 55. Du Bois J, Trehu E, Mier J, et al. Randomized placebo controlled clinical trial of high-dose inlerleukin-2 (IL-2) in combination with the soluble TNF receptor IgG chimera (TNFR:Fc) [abstract no. 704]. Proc Am Soc Clin Oncol 1995 Mar; 14: 258
56. 56. Bozkurt B, Torre-Amione G, Soran OZ, et al. Results of a multidose phase 1 trial with tumor necrosis factor receptor (p75) fusion protein (Etanercept) in patients with heart failure [abstract no. 1110-14], J Am Coll Cardiol 1999 Feb; 33 Suppl. A: 184A
57. 57. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548-61
58. 58. Jacobs CA, Beckmann MP, Mohler K, et al. Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int Rev Exp Pathol 1993; 34B: 123-35
59. 59. Wee S, Pascual M, Eason JD, et al. Biological effects and late of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy. Transplantation 1997 Feb 27; 63: 570-7
60. 60. Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein un type II collagen-induced arthritis in mice. J Immunol 1993; 151: 6602-7
61. 61. Moreland LW, Bucy RP, Weinblatt MB, et al. Effets of TNF receptor (P75) fusion protein (TNFR:Fc;Enbrel) on immune function [abstract no. 158]. Arthritis Rheum 1998; 41 Suppl.: S59
62. 62. Chatham WW, McDuffie D, Zhang L, et al. Effects of rhuTNFR:Fc on neutrophil function [abstract]. Arthritis Rheum 1997 Sep; 40 Suppl.: S81
63. 63. Nam MH, Reda D, Boujoukos AJ, et al. Recombinant human dimerie tumor necrosis factor (TNF) receptor (TNFR:Fc): safely and pharmacokinetics in human volunteers. Clin Res 1993; 41 (2): 249A
64. 64. Lebsack ME, Hanna RK, Lange MA, et al. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers [abstract]. Pharmacotherapy 1997 Sep-Oct; 17: 1118-9
65. 65. Moreland LW, Margolies G, Heck JLW, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996 Nov; 23: 1849-55
66. 66. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Mod 1997 Jul 17; 337: 141-7
67. 67. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of Etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 Jan 28; 340: 253-9
68. 68. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled study. Ann Intern Med 1999; 130; 478-86
69. 69. Hochberg MC, Chang RW, Dwosh I, et al. American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498-502
70. 70. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38: 727-35
71. 71. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40
72. 72. Epstein WV. Expectation bias in rheumatoid arthritis clinical trials: the anti-CD4 monoclonal antibody experience. Arthritis Rheum 1996 Nov; 39: 1773-80
73. 73. Epstein WV. Treatment of rheumatoid arthritis with a tumor necrosis factor receptor-Fc fusion protein [letter and discussion]. N Engl J Med 1997 Nov 20; 337: 1559-61
74. 74. Moreland LW, Widmer MB, Blosch CM. Treatment of rheumatoid arthritis with a tumor necrosis factor receptor-Fc fusion protein [reply: letter]. N Engl J Med 1997; 337: 1560-1
75. 75. Baumgartner SW, Moreland LW, Schiff MH, et al. Response of elderly patients to the TNF receptor p75 FC fusion protein (TNFR:FC;Enbrel) [abstract no. 160]. Arthritis Rheum 1998; 41 Suppl.: S59
76. 76. Moreland L, Blosch C, Colwell H, et al. Functioning and well-being of DMARD-failed rheumutoid arthritis patients receiving P75 TNFR:FC (Enbrel) [abstract no. 159]. Arthritis Rheum 1998; 41 Suppl.: S59
77. 77. Moreland LW, Baumgartner SW, Tindall EA, et al. Long term safety and efficacy ot Etanercept (Enbrel) in DMARD refractory rheumatoid arthritis (RA) [abstract]. XIV European League Against Rheumatism (EULAR) Congress; 1999 Jun 6-11; Glasgow
78. 78. Lovell DJ, Giannini EH, Whitmore JB, et al. Safety and efficacy of tumor necrosis factor receptor p75 FC fusion protein (TNFR:FC; Enbrel) in polyarticular course juvenile rheuma toid arthritis [abstract no. 584]. Arthritis Rheum 1998; 41 Suppl.: S130
79. 79. Giannini EH, Ruperto N, Raveili A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40; 1202-9
80. 80. Terranova PF, Hunter VJ, Rohy KF, et al. Tumor necrosis factor-α in the female reproductive tract. Proc Soc Exp Biol Med 1995; 209: 325-42
81. 81. Robertson SA, Seamark RF, Guilbert LJ, et al. The role of cytokines in gestation. Crit Rev Immunol 1994; 14: 239-92
82. 82. Pincus T. Long term outcomes in rheumatoid arthritis. Br J Rheumatol 1995 Nov; 34 Suppl. 2: 59-73
83. 83. Callahan LF. The burden of rheumatoid arthritis: facts and figures. J Rheumatol 1998 Jul; 25 Suppl. 53: 8-12
84. 84. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35: 781-90
85. 85. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol 1996; 23 Suppl. 44: 47-51
86. 86. Wolfe F, Kleinheksel SM, Spitz PW. et al. A multicenter study of hospitalisation in rheumatoid arthritis; effect of health care system severity and regional difference. J Rheumatol 1986; 13: 277-84
87. 87. American College of Rheumatology Ad Hoc Committee On Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713-22
88. 88. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989; 96: 647-55
89. 89. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 213-22
90. 90. Kirwan JR, The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142-6
91. 91. Hickling P, Jacoby RK, Kirwan JR, et al. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998; 37: 930-6
92. 92. Yocum DE. Glucocorticoids in rheumatoid arthritis: lessons for the future. Br J Rheumatol 1998; 37: 1145-7
93. 93. Weinblatt ME. Rheumatoid arthritis: treat now, not later! Ann Intern Med 1996; 124: 773-4
94. 94. Jain R, Lipsky PE. Treatment of rheumatoid arthritis. Adv Rheumatol 1997; 81: 57-84
95. 95. van Gestel AM, Haagsma CJ, Furst DE, et al. Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDS). Baillieres Clio Rheumatol 1997; 11: 65-82
96. 96. Scott DL. Clinical guidelines for management. Baillieres Clin Rheumatol 1997; 11: 157-79
97. 97. Box SA, Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. Br J Rheumatol 1997 Mar; 36: 382-6
98. 98. Rozman B, Leflunomide Investigators Group. Clinical experience with leflunomide in rheumatoid arthritis. J Rheumatol 1998 Jul; 25 Suppl. 53: 27-32
99. 99. Gaffney K, Stott DGI. Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Br J Rheumatol 1998 Aug; 37: 824-36
100. 100. Furst DE. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br J Rheumatol 1997 Nov; 36: 1196-204
101. 101. Jones G, Brooks PM. Injectable gold compounds; an overview. Br J Rheumatol 1996 Nov; 35: 1154-8
102. 102. Kean WF, Hart L, Buchanan WW. Auranofin. Br J Rheumatol 1997 May; 36: 560-72
103. 103. Chaudhuri K, Torley H, Madhok R. Cyclosporin. Br J Rheumatol 1997 Sep; 36: 1016-21
104. 104. Munro R, Capell HA. Penicillamine. Br J Rheumatol 1997; 36: 104-9
105. 105. Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 1997; 36: 799-805
106. 106. American College of Rheumatology Ad Hoc Committee On Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 723-31
107. 107. Anon, Arava (leflunomide) prescribing information. Hoechst Marion Roussel Inc., Kansas City, Missouri, 1998 Sep
108. 108. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994; 330; 1368-75
109. 109. Corner M, Scott DL, Doyle DV, et al. Are slow-acting anti-rheumatic drugs monitored too often? An audit of current clinical practice. Br J Rheumatol 1995; 34: 966-70
110. 110. Farr M, Bacon PA. How and when should combination therapy he used? The role of an anchor drug. Br J Rheumatol 1995 Nov; 34 Suppl. 2: 100-3
111. 111. Wolfe F. Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis. Clin Exp Rheumatol 1997; 15 Suppl. 17: S75-81
112. 112. O'Dell J. Combination DMARD therapy for rheumatoid arthritis: apparent universal acceptance [abstract]. Arthritis Rheum 1997; 40 Suppl.: S50
113. 113. Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Biodrugs 1998; 10: 397-422
114. 114. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7
115. 115. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63